New hope for hard-to-treat breast cancer? early trial combines two targeted drugs

NCT ID NCT05501769

Completed Disease control Sponsor: Arvinas Estrogen Receptor, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new combination of two drugs (ARV-471 and everolimus) in 32 people with a common type of advanced breast cancer (ER+/HER2-). The main goals were to find the safest dose and check for side effects. Researchers also looked at whether the tumors shrank or stayed stable. This study is for patients who have already tried other treatments, including CDK4/6 inhibitors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Clinical Trial Site

San Diego, California, 92037, United States
Clinical Trial Site

Santa Monica, California, 90404, United States
Clinical Trial Site

Washington D.C., District of Columbia, 20007, United States
Clinical Trial Site

Lake Mary, Florida, 32746, United States
Clinical Trial Site

Ann Arbor, Michigan, 48109, United States
Clinical Trial Site

Nashville, Tennessee, 37203, United States
Clinical Trial Site

Barcelona, 08028, Spain
Clinical Trial Site

Madrid, 28034, Spain
Clinical Trial Site

Valencia, 46018, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.